A personalized digital approach to cancer risk assessment in a diverse gynecology clinic.
Abstract
e22642 Background: Most individuals who qualify for cancer genetic testing and enhanced breast cancer screening are not identified. We aim to sustainably integrate digital cancer risk assessment into the daily workflow of a gynecology clinic. Methods: In an effectiveness-implementation quality improvement (QI) study in an urban academic gynecology practice serving patients with public insurance, a digital tool (DT) for cancer risk assessment was launched to identify those who meet NCCN (National Comprehensive Cancer Network) criteria for hereditary cancer screening and generate a Tyrer-Cuzick (TC) score. New gynecology patients > 18 years were invited to complete the DT via secure portal-based text messaging. Data were collected through chart review. Statistical analysis was performed using Stata version 19. Results: During 6 weeks pre-implementation, 131 new gyn visits were seen (median age 42). At least 14 (10.7%) patients were eligible for genetic testing by NCCN criteria, among which 1 was counseled and 3 had prior testing. Only 1 patient had a TC score calculated. In the initial 6 weeks post-implementation, 171 new patients were seen (median age 41), of which 153 were sent the DT with 82 (53.6%) completing it. Among this group, 18 (22.0%) met NCCN criteria for genetic testing and 12 (14.6%) had a TC score exceeding 20%. 21 of 24 (87.5%) patients meeting NCCN criteria and/or with an elevated TC score were counseled and/or referred to Genetics and Personalized Cancer Prevention Program (GPCP). In the first 6 weeks post-implementation, the QI team was onsite providing education and assistance. In the subsequent 5 weeks, there was no difference in DT completion rates (53.6% vs. 51.1% respectively, p = 0.70). In the absence of the QI team, there was a significant increase in “missed patients" (0% vs. 40% respectively, p < 0.001). For “missed patients” or patients with abnormal results on the DT that were not counseled, the QI team contacted the provider and encouraged follow-up with the patient. Conclusions: The QI initiative demonstrated a short-term sustainable effort to screen patients for increased cancer risk, with challenges in follow-up identified. This quality improvement project is working iteratively to implement universal personalized risk-based cancer prevention. Pre-Implementation(6 weeks, n = 131)n / n (%) Post-Implementation (6 weeks, n = 153)n / n (%) p-value Completed DT / Received DT - 82 / 153 (53.6) - Meet NCCN criteria for genetic testing 14 / 131 (10.7) 18 / 82 (22.0) - TC Score Calculated 1 / 131 (0.76) 77 / 153 (50.3) < 0.001 TC Score > 20% 0 / 1 (0) 12 / 82 (14.6) - Meet NCCN and/or TC Score > 20% 14 / 131 (10.7) 24 / 82 (29.3) - Referred to GPCP 0 / 14 (0) 14 / 24 (58.3) < 0.001 Documented discussion of risk/Genetic testing already done/Prior GPCP Referral/Declined GPCP Referral 4 / 14 (28.6) 7 / 24 (29.2) 0.97 Cancelled Appointment - 3 / 24 (12.5) - No documented discussion of risk or GPCP referral (missed) 10 / 14 (71.4) 0 / 24 (0) < 0.001
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (11)
Hannah Grace Peifer
New York Presbyterian - Weill Cornell Department of Obstetrics and Gynecology, New York, NY
Enzo Gallo Bruscato
Genetics and Personalized Cancer Prevention Program, Weill Cornell Medicine, New York, NY
Amanda Laterza Ozarowski
Genetics and Personalized Cancer Prevention Program, Weill Cornell Medicine, New York, NY
Michelle Primiano
Genetics and Personalized Cancer Prevention Program, Weill Cornell Medicine, New York, NY
Siena Gioia
Genetics and Personalized Cancer Prevention Program, Weill Cornell Medicine, New York, NY
Max Kirby
Genetics and Personalized Cancer Prevention Program, Weill Cornell Medicine, New York, NY
Tina Karimaghaie
Genetics and Personalized Cancer Prevention Program, Weill Cornell Medicine, New York, NY
Steve Lopez
Department of Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
Christina Pardo
Women's Health Practice, Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY
Ravi Sharaf
Department of Medicine, Weill Cornell Medicine, New York, New York, NY
Melissa Kristen Frey
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY